This phase 0 first-in-human study evaluated the biodistribution, normal-tissue dosimetry, and tumor targeting of 111In-radiolabeled h11B6 ([111In]-DOTA-h11B6) to evaluate hK2 as a target in patients with mCRPC. This evidence concerns the gene HK2 and neoplasm.